FromAstraZeneca ([email protected])
Subject (134)Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer
Preheader (150)Datopotamab deruxtecan showed median overall survival of 14.6 months in patients with advanced nonsquamous non-small cell lung cancer in TROPION-Lung0
Arial
Text Analysis
Body Words239
Subject Words18
Body Emojis1
Subject Emojis
Media Analysis
Text Links8
Image Links4
Total Links12
Images7
Technical Metrics
Performance
HTML Size, Kb
Pixel Length, px814 px
X-Spam Score-0.2
Preheader OptimizedNo
Timing
Day of WeekFriday
TimeEvening
